Publicaciones científicas

Búsqueda avanzada

Inicio
> Grupos de Investigación
> Área de Cáncer
> Laboratorio de oncología molecular y celular

Laboratorio de oncología molecular y celular

Personalized therapies in the cancer "omics" era
Ocaña A, Pandiella A.
Molecular Cancer 9:202. FI: 4.160 (Q2)
PubMed
Do we have to change the way targeted drugs are developed
Ocaña A, Amir E, Seruga B, Pandiella A.
Journal of Clinical Oncology 28(24):e420-1. FI: 17.793 (Q1)
PubMed
Deficient Spindle Assembly Checkpoint in Multiple Myeloma
MARÍA ELENA DIAZ Rodríguez; Stela Álvarez Fernández; Xi Chen Chen; Bruno David Lourenço Paiva; Ricardo Lopez-Perez; Juan Luis García Hernández; Jesús Fernando San Miguel Izquierdo; Atanasio Pandiella
Plos One 6: -0. FI: 4,411(Q1)
Reversibility of the Resistance to Lenalidomide and Pomalidomide and Absence of Cross-Resistance in a Murine Model of MM
Enrique M Ocio San Miguel; Diego Fernández Lázaro; Laura San Segundo Payo; LORENA González MENDEZ; Mª Montserrat Martín Sánchez; Mercedes Garayoa Berrueta; Teresa Paíno Gómez; Antonio García Gómez; Norma Carmen Gutiérrez Gutiérrez; Manuel Delgado Criado; Juan Carlos Montero González; Nuria Quintana; Jose Luis Garcia; Atanasio Pandiella ; Jesús Fernando San Miguel Izquierdo
Blood 118: 65-0. FI: 10,558(Q1)
Biological and Clinical Significance of CD81 Expression by Clonal Plasma Cells in High-Risk Smoldering and Symptomatic Multiple Myeloma (MM) Patients
Bruno David Lourenço Paiva; Norma Carmen Gutiérrez Gutiérrez; Xi Chen Chen; María Belén Vidriales Vicente; Maria-Angeles Montalban; Laura Rosinol; Albert Oriol; Joaquin Martinez-Lopez; María Victoria Mateos ; Lucía López Corral; MARÍA ELENA DIAZ Rodríguez; José Juan Pérez Morán; Elena Fernandez-Redondo; Felipe de Arriba; Luis Palomera; Enrique Bengoechea; Maria Jose Terol; Raquel de Paz; Alejandro Martín García Sancho; Jose Hernandez; JOSE ALBERTO ORFAO DE MATOS CORREIA E VALE; Juan Jose Lahuerta; Joan Blade; Atanasio Pandiella ; Jesús Fernando San Miguel Izquierdo
Blood 118: 1682-1683. FI: 10,558(Q1)
A modular approach to trim cellular targets in anticancer drug discovery
Carla Rios-Luci; Raquel Dominguez-Kelly; Leticia G. Leon; MARÍA ELENA DIAZ Rodríguez; Raimundo Freire; Atanasio Pandiella ; Inga Cikotiene; Jose M. Padron
Bioorganic & Medicinal Chemistry Letters 21: 6641-6645. FI: 2,661(Q2)
Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors
Juan Carlos Montero González; Samuel Seoane ; Alberto Ocana; Atanasio Pandiella
Clinical Cancer Research 17: 5546-5552. FI: 7,338(Q1)
Transautocrine Signaling by Membrane Neuregulins Requires Cell Surface Targeting, Which Is Controlled by Multiple Domains
Juan Carlos Montero González; Ruth Rodriguez-Barrueco; Atanasio Pandiella
Journal Of Biological Chemistry 286: 24350-24363. FI: 5,328(Q1)
Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response
Enrique Colado; Teresa Paíno Gómez; Patricia Maiso; Enrique M Ocio San Miguel; Xi Chen Chen; Stela Álvarez Fernández; Norma Carmen Gutiérrez Gutiérrez; Jesus Martin-Sanchez; Juan Alejandro Flores Montero; Laura San Segundo Payo; Mercedes Garayoa Berrueta; Diego Fernández Lázaro; María Belén Vidriales Vicente; Carlos M. Galmarini; Pablo Aviles; Carmen Cuevas; Atanasio Pandiella ; Jesús Fernando San Miguel Izquierdo
Haematologica-The Hematology Journal 96: 687-695. FI: 6,532(Q1)
P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer
Juan Carlos Montero González; Samuel Seoane ; A. Ocana; Atanasio Pandiella
Oncogene 30: 1059-1071. FI: 7,414(Q1)

45 resultados

Páginas: < 1 2 3 4 5 >

NoticiasNoticias
Zona del InvestigadorZona del Investigador